

PAIN AND DEPRESSION IN PATIENTS WITH OSTEOARTHRITIS – AN EPIDEMIOLOGICAL STUDY

B. Sharath Babu^{1*}, Kavi. Manasa²,

Ramya Sree Kajjam² and Manasa Reddy Katukoori²

¹Department of Pharmacology, Vaagdevi Institute of
Pharmaceutical Sciences, Warangal, Telangana, India.

²Department of Pharmacy practice, Vaagdevi Institute
of Pharmaceutical Sciences, Warangal, Telangana, India.

ABSTRACT

Osteoarthritis (OA) is the most common form of arthritis. It is a disease that affects all the tissues of the joint, including the cartilage, bone, ligaments, and muscles. It can develop in any number of joints, but most commonly affects the knees, hands, and hips. A prospective observational study in MGMH, Warangal with sample size of 400-500 subjects for six months. In the present study, subjects aged 50 years and above were shown as significantly high OA risk among the elderly. Based on our research on preferring a standard pain evaluating scale, many studies have shown a peremptory response towards the WOMAC Osteoarthritis index scale that has proved significantly more responsive, especially in the measurement of function. The impact of depression on patients with OA has been documented in many aspects: despite the impact on quality of life, depression has been revealed as a negative predictor of the outcome of surgical interventions and interventions aimed at physical activity.

Keywords: Osteoarthritis (OA), WOMAC Osteoarthritis index scale and osteophytic lipping.

INTRODUCTION

Osteoarthritis (OA) is the most common form of arthritis. It is a disease that affects all the tissues of the joint, including the cartilage, bone, ligaments, and muscles. It can develop in any number of joints, but most commonly affects the knees, hands, and hips¹. It is a disease that damages the slippery tissue that covers the ends of bones in a joint². In normal joints, a firm, rubbery material called cartilage covers the end of each bone. Cartilage provides a smooth, gliding surface for joint motion and acts as a cushion between the bones. In OA, the cartilage breaks down, causing pain, swelling and problems moving the joint⁴.

Osteoarthritis first shows itself as a change to the biological processes within a joint, followed by abnormal changes to the joint itself (such

as the breakdown of cartilage, bone reshaping, bony lumps, joint inflammation, loss of joint function). This can result in pain, stiffness and loss of movement³.

As OA worsens over time, bones may break down and develop growths called spurs. Bits of bone or cartilage may chip off and float around in the joint. In the body, an inflammatory process occurs and cytokines (proteins) and enzymes develop that further damage the cartilage. In the final stages of OA, the cartilage wears away and bone rubs against bone leading to joint damage and more pain⁴. OA is considered a chronic (long-lasting) disease and other than joint replacement surgery there is presently no cure. There are, however, treatments that can reduce pain, improve function, and in some

instances delay the progression of the disease¹.

Stages of Osteoarthritis⁵

The Kellgren and Lawrence system is a common method of classifying the severity of knee (OA) using five grades. This classification was proposed by Kellgren et al. in 1957 and later accepted by WHO in 1961.

Grade 0: no radiographic features of OA are present

Grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping

Grade 2: definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph

Grade 3: multiple osteophytes, definite JSN, sclerosis, possible bony deformity

Grade 4: large osteophytes, marked JSN, severe sclerosis and definite bony deformity.

Global Status of Osteoarthritis

OA accounts as most prevalent musculoskeletal disease among the world (Felson DT *et al*, 1998), and is most common reasons of joint disability in approximately 100 million people among world having age over 45 years (Hinman RS *et al*, 2010), which is approximately 15% of all musculoskeletal disorders (National Collaborating Centre for Chronic Conditions, 2008) (figure-1). More than 50% population over 65 years have radiographic confirmation of OA in any of the joints and younger population is prone to injury-induced OA.

Europe and USA reflect highest worldwide frequency of OA (Haq I *et al*, 2003). 18% of women and 9.6% of men are universally reported with symptomatic OA in 60 years and higher age group (Wolf AD *et al*, 2003). Globally Knee OA is 4th most significant cause of incapability in women and 8th in men (Azad CS *et al*, 2015). The EULAR (European League against Rheumatism) report expresses 30% radiographic evidence of knee OA over the age of 65 years (Jordan KM *et al*, 2003).

Osteoarthritis grade in India

In Indian impact, nearly 80% of population shows OA among the patient who claimed for knee pain, out of which approximately 20% reported incapability in daily activities and around 11% need peculiar care (Hinman RS Ringdahl E *et al*, 2011). Approximately 40% population of more than 70 years shows OA, in which nearly 2% have severe knee pain and disability (Jain S, 2011). Increment in age exponentially increases the allied risk of OA, due to progressive changes in routine diet, working milieu conditions and lifestyle patterns

et al, 2011). The incidence of knee OA increase 10 folds amongst the ages of 30 and 65 years (Magrans C T *et al* distribution/contribution of OA in different states in India reported in figure-3. A survey based study reveals that, "India is predicted as chronic disease capital by 2025 have 60 million people with arthritis" (Jain S, 2011).

1. Patients of age between 25-80 years who are diagnosed as osteoarthritis.
2. Patients who are receiving treatment for osteoarthritis.
3. Subjects who are accessible through consent and cooperate to this study.

MATERIALS AND METHODS

A prospective observational study In MGMH, Warangal with sample size of 400-500 subjects for six months. Patients of age between 25-80 years who are diagnosed as osteoarthritis. Patients who are receiving treatment for osteoarthritis. Subjects who are accessible through consent and cooperate to this study. Patients who are not receiving treatment for osteoarthritis. Subjects who are not willing to participate in this study. Subjects who are psychologically ill, deaf and non-cooperative to this study. The data collection form includes all the patient's required details along with the WOMAC OSTEOARTHRITIS INDEX (WOMAC) (26 questions) and PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)

RESULTS AND DISCUSSION

Fig. 1: Description of various age groups of study participants (N=523)

Many studies showed increasing age to be a risk factor for OA. Females had high WOMAC score percentage (56.6%) compared to Males (43.4%). This was consistent with higher incidence rates of knee OA in women than men with high risk WOMAC score percentage.

Fig. 2: Frequency of co-morbid conditions associated with Osteoarthritis in study participants (N=523)

There is mixed evidence of the association of hypertension, diabetes and obesity with the onset of knee OA with few showing significant positive association and few revealing no association. Our study shows a relatively positive significance between the chronic diseases like hypertension, diabetes and obesity with osteoarthritis. Other chronic diseases like thyroid disorders were not found to have any effect on WOMAC scores in the study.

Fig. 3: Total Score of PHQ-9 (Out of 27)

The **PHQ-9** is a completely self administered questionnaire that enables screening for depression and assessment of depression severity. For each of the 9 depressive symptoms according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (22), patients indicated whether, during the previous 2 weeks, the symptom had bothered them “not at all,” “several days,” “more than half the days,” or “nearly everyday,” yielding as core of 0–3. The PHQ-9 severity score thus ranges from 0 to 27.

Table 1: Frequency of psychological problems among the participants (N=523)

Regarding the PHQ-9, 227 men (43.4%) and 296 women (56.6%).

The categories of depression severity according to the PHQ9 are displayed in Table 5 with the categories

None-Score 1–4,

Mild-Score 5–9,

Moderate-Score 10–14,

Moderately severe-Score 15–19,

And Severe-Score 20–27.

73 (13.9%) participants were classified as not depressed. With a score of 10; 140 (26.7%) participants were depressed. Using a cut off score of 15, a total of 174 (33.2%) patients and with a cut off score of 20; 136 (26%) participants were classified as extremely depressed.

Table 2: Severity of pains

Fig. 4: The following questions concern physical function. By this we mean ability to move around and to look after yourself. For each of the following activities, please indicate the degree of difficulty you have experienced in the last 48 hours, in your knees. What degree of difficulty do you have with.

Females had a high WOMAC score percentage (56.6%) compared to The study also shown the increased risk of affecting the body part involved in OA is right knee (50.3%) exhibiting typical pain while waking at night (timing of pain) (49.8%). Patients experienced more pain while walking on a flat surface (quantity of pain) (50.4%) and observed severe difficulty (physical function with a degree of difficulty) in performing light domestic duties (such as tidying a room, dusting, cooking) (53.9%) and extreme difficulty in performing heavy domestic duties (moving in the lawn, lifting heavy grocery bags) (40.3%). There is also evidence that specific occupations were risk factors for knee

pain, for example, farming, construction work, standing (>2 h per day).

There is combined evidence showing the association between hypertension, diabetes, and obesity with OA with few showing significant positive associations and few revealing no association. Our study shows relatively positive significance between chronic diseases like hypertension (35.1%), diabetes (15.7%), and overweight/obesity (35.9%) with OA.

Based on earlier findings showing biological differences (e.g. regarding the destruction of the cartilage) and psychological differences (e.g. perception of pain), we hypothesized that men and women differ regarding many aspects of QoL and received care. This hypothesis could be confirmed. OA has a higher impact on women in important aspects of QoL such as pain, disability, and mood. Similar gender differences have been found e.g. by Woo et al. among Chinese people.

Most of the patients received NSAID (Diclofenac 50 mg), calcium 500 mg, and multivitamin tablets for the treatment of OA and tended to have less intraarticular injections in our study.

In the present study, we utilized the PHQ-9 scale to evaluate the impact of depression in OA patients. The PHQ-9 is a completely self-administered questionnaire that enables screening for depression and assessment of depression severity. For each of the 9 depressive symptoms according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (22), patients indicated whether, during the previous 2 weeks, the symptom had bothered them “not at all,” “several days,” “more than half the days,” or “nearly every day,” yielding a score of 0–3. The PHQ-9 severity score thus ranges from 0 to 27.

Regarding the PHQ-9, 227 men (43.4%) and 296 women (56.6%) answered all 9 items. The categories of depression severity according to the PHQ-9 are displayed in Table 5 with the categories none (score 1–4), mild (score 5–9), moderate (score 10–14), moderately severe (score 15–19), and severe (score 20–27). 73 (13.9%) participants were classified as not depressed. With a score of 10; 140 (26.7%) participants were depressed. Using a cut-off score of 15, a total of 174 (33.2%) patients and with a cut-off score of 20; 136 (26%) participants were classified as extremely depressed.

CONCLUSION

In conclusion, the impact of depression on patients with OA has been documented in many aspects, despite the impact on the

quality of life, depression has been revealed as a negative predictor of the outcome of surgical interventions and interventions aimed at physical activity. As in the general population, depression influences consulting behaviour and increases health service utilization. In contrast, previous findings indicate that physicians overestimate structural changes in OA and underestimate the contribution of depression to pain perception,

functional ability, and quality of life. Furthermore, previous studies have demonstrated that improved depression care can improve pain and functional ability among patients with OA.

ACKNOWLEDGMENT

We thank B. Sharath Babu for keen guidance and cooperation in the work management.

Table 1: Frequency of psychological problems among the participants (N=523)

S.No	Question	No total(0)	Several days(1)	More than half the days(2)	Nearly every day (3)
1	Little interest or pleasure in doing things	0.76%	5.35%	29.83%	64.05%
2	Feeling down, depressed, or hopeless	0.19%	12.24%	30.59%	56.98%
3	Trouble falling or staying asleep, or sleeping too much	0.96%	16.06%	35.76%	47.23%
4	Feeling tired or having little energy	0.96%	24.86%	40.73%	33.46%
5	Poor appetite or overeating	3.25%	22.56%	48.18%	26.00%
6	Feeling bad about yourself or that you are a failure or have let yourself or your family down	13.58%	23.14%	47.80%	15.49%
7	Trouble concentrating on things, such as reading the news paper or watching television	27.15%	24.47%	37.28%	11.09%
8	Moving or speaking so slowly that other people could have noticed. Or the opposite being so fidgety or restless that you have been moving around a lot more than usual	49.52%	25.24%	20.08%	5.16%
9	Thoughts that you would be better off dead, or of hurting yourself in some way	71.70%	19.31%	8.99%	0.00%

Table 2: Severity of pains

S.No	Variable	%	
01.	Body part involved in OA		
		Right	Left
	Neck	9.04%	5.97%
	Shoulder	10.26%	4.29%
	Elbow	1.15%	0.76%
	Hip	16.37%	14.57%
	Knee	50.36%	49.43%
	Spine	6.29%	5.94%
	Wrist	1.70%	1.51%
	Ankle	0.57%	0.95%
02.	Quality of pain		
	Sharp	3.23%	
	Dull with aching	3.53%	
	Stabbing	49.36%	
	Throbbing	43.19%	
	Burning	0.69%	
03.	Timing of pain		
	Constant	36.56%	
	Infrequent	13.63%	
	Waking at night	49.81%	
04.	Pain control measures by patients		
	Rest	50.98%	
	Ice	0.39%	
	Elevation	0.00%	
	Medication	48.62%	




Fig. 1: Description of various age groups of study participants (N=523)




Fig. 2: Frequency of co-morbid conditions associated with Osteoarthritis in study participants (N=523)




Fig. 3: TotalScoreofPHQ-9 (Out of 27)




Fig. 4: The following questions concern physical function. By this we mean ability to move around and to look after yourself. For each of the following activities, please indicate the degree of difficulty you have experienced in the last 48hours, in your knees. What degree of difficulty do you have with.

REFERENCES

1. World Health Organization. World Health Report 2002.Reducing Risks, Promoting Healthy Life. Geneva: WHO. 2002;Felson DT.
2. The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. *SeminArthritis Rheum.* 1990;20:42-50.
3. Rajan SI, Sarma PS and Mishra US. Demography of Indian aging. 20012051.*J Aging Soc Policy.* 2003;15:11-30.
4. Melzer D, Guralnik JM and Brock D: Prevalence and distribution of hip and knee joint replacements and hip implants in older Americans by the end of life. *Aging Clin Exp Res.* 2003;15:60-6.
5. D'Ambrosia RD. Epidemiology of osteoarthritis. *Orthopedics.* 2005;28:201-5.
6. LaValley M, McAlindon TE, Evans S, Chaisson CE and Felson DT. Problems in the development and validation of questionnaire-based screening instruments for ascertaining cases with symptomatic knee osteoarthritis: the Framingham Study. *Arthritis Rheum.* 2001;44:1105-13.
7. Collins NJ, Misra D, Felson DT, Crossley KM and Roos EM. Measures of Knee Function. *Arthritis Care Res (Hoboken).* 2011;63(11):208-28.
8. Corti MC and Rigon C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. *Aging Clin Exp Res.* 2003;15:359-63.
9. Liang MH, Meenan RF, Cathcart ES and Schur PH. A screening strategy for population studies in systemic lupus erythematosus. Series design. *Arthritis Rheum.*1980;23:153-7.
10. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J and Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol.* 1988;15:1833-40.
11. Bischoff HA, Roos EM and Liang MH. Outcome assessment in osteoarthritis: a guide for research and clinical practice. In: Brandt KD, Doherty M, LohmanderLS, eds. *Osteoarthritis* New York: Oxford University Press. 2003;381-90.
12. Bellamy N. WOMAC: A 20-year experiential review of a patient-centered self-reported health status questionnaire. *J Rheumatol.* 2002;29:2473-6.
13. Bellamy N. WOMAC Osteoarthritis Index user guide. London (Ontario, Canada): University of Western Ontario. 1995.
14. Reginster JY. The prevalence and burden of arthritis. *Rheumatology.* 2002;41:3-6.
15. Sharma L, CahueS, Song J, Hayes K, Pai YC and Dunlop D. Physical functioning over three years in knee osteoarthritis: role of psychosocial, local, mechanical, and neuromuscular factors. *Arthritis Rheum.* 2003;48:3359-3370.
16. Jette AM, Haley SM, CosterWJ, Kooyoomjian JT, Levenson S and Heeren T. Late life function and disability instrument (FDI). *J Gerontol ABiolSci Med Sci.* 2002;57:209-216.
17. Murray CJL and Lopez DL. Global mortality, disability, and the contribution of risk factors: global burden of disease study. *Lancet.* 1997;349:1436-1442.
18. Woolf AD and Pfleger B. Burden of major musculoskeletal conditions. *Bull WHO.* 2003; 81:646-656.
19. Angst F, Aeschlimann A and Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Rheum.* 2001;45:384-391.
20. Jaeschke R, Singer J and Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. *Control Clin Trials.* 1989;10:407-415.